Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Brain Stem Neoplasms | 16 | 2020 | 190 | 3.930 |
Why?
|
Brain Neoplasms | 45 | 2024 | 8980 | 2.770 |
Why?
|
Glioma | 26 | 2024 | 3417 | 2.390 |
Why?
|
Magnetic Resonance Imaging | 75 | 2024 | 36230 | 1.390 |
Why?
|
Fluorodeoxyglucose F18 | 5 | 2017 | 2007 | 1.170 |
Why?
|
Neurofibromatosis 1 | 7 | 2022 | 561 | 1.010 |
Why?
|
Diagnostic Imaging | 11 | 2023 | 3526 | 0.950 |
Why?
|
Positron-Emission Tomography | 9 | 2018 | 6457 | 0.920 |
Why?
|
Medulloblastoma | 9 | 2022 | 677 | 0.850 |
Why?
|
Child | 107 | 2024 | 79759 | 0.820 |
Why?
|
Central Nervous System Neoplasms | 9 | 2022 | 917 | 0.820 |
Why?
|
Phantoms, Imaging | 5 | 2018 | 2510 | 0.740 |
Why?
|
Infratentorial Neoplasms | 4 | 2021 | 98 | 0.650 |
Why?
|
Child, Preschool | 73 | 2024 | 42036 | 0.630 |
Why?
|
Magnetic Resonance Spectroscopy | 11 | 2019 | 3764 | 0.620 |
Why?
|
Cerebellar Neoplasms | 6 | 2022 | 585 | 0.600 |
Why?
|
Image Interpretation, Computer-Assisted | 6 | 2024 | 3333 | 0.590 |
Why?
|
Cerebral Ventricles | 8 | 2012 | 543 | 0.580 |
Why?
|
Neuroradiography | 1 | 2015 | 71 | 0.510 |
Why?
|
Nuclear Medicine | 1 | 2018 | 236 | 0.510 |
Why?
|
Brain Stem | 3 | 2019 | 857 | 0.470 |
Why?
|
Ependymoma | 4 | 2022 | 320 | 0.470 |
Why?
|
Astrocytoma | 4 | 2008 | 775 | 0.430 |
Why?
|
Central Nervous System Diseases | 2 | 2015 | 521 | 0.430 |
Why?
|
Radiopharmaceuticals | 2 | 2014 | 2633 | 0.420 |
Why?
|
Neurology | 3 | 2018 | 779 | 0.420 |
Why?
|
Adolescent | 70 | 2024 | 87749 | 0.410 |
Why?
|
Diffusion Magnetic Resonance Imaging | 5 | 2022 | 2775 | 0.410 |
Why?
|
Infant | 45 | 2024 | 36032 | 0.400 |
Why?
|
Surface Plasmon Resonance | 2 | 2022 | 265 | 0.390 |
Why?
|
Tomography, X-Ray Computed | 15 | 2019 | 20483 | 0.390 |
Why?
|
Neurofibroma, Plexiform | 3 | 2013 | 66 | 0.370 |
Why?
|
Headache | 1 | 2019 | 1249 | 0.370 |
Why?
|
Brain | 21 | 2022 | 26905 | 0.370 |
Why?
|
Research Report | 1 | 2013 | 370 | 0.350 |
Why?
|
Benzimidazoles | 4 | 2022 | 858 | 0.320 |
Why?
|
Humans | 143 | 2024 | 760276 | 0.320 |
Why?
|
Meningeal Neoplasms | 5 | 2018 | 1248 | 0.310 |
Why?
|
Societies, Medical | 2 | 2018 | 3903 | 0.310 |
Why?
|
Image Processing, Computer-Assisted | 6 | 2023 | 8935 | 0.290 |
Why?
|
Organizations | 1 | 2008 | 171 | 0.280 |
Why?
|
Clinical Trials as Topic | 3 | 2018 | 8058 | 0.280 |
Why?
|
Spinal Cord Diseases | 1 | 2009 | 293 | 0.280 |
Why?
|
Pediatrics | 3 | 2015 | 3587 | 0.280 |
Why?
|
Quinolones | 4 | 2011 | 377 | 0.280 |
Why?
|
Neuroectodermal Tumors | 1 | 2006 | 22 | 0.270 |
Why?
|
Male | 85 | 2024 | 359427 | 0.270 |
Why?
|
Spinal Cord Neoplasms | 3 | 2022 | 264 | 0.260 |
Why?
|
Radiation Injuries | 3 | 2019 | 1183 | 0.260 |
Why?
|
Female | 89 | 2024 | 391024 | 0.260 |
Why?
|
Multicenter Studies as Topic | 2 | 2010 | 1723 | 0.260 |
Why?
|
Back Pain | 1 | 2009 | 543 | 0.260 |
Why?
|
Hypothalamic Neoplasms | 3 | 2005 | 21 | 0.260 |
Why?
|
Quinazolines | 4 | 2015 | 1363 | 0.250 |
Why?
|
Spinal Diseases | 2 | 2009 | 559 | 0.250 |
Why?
|
Retrospective Studies | 30 | 2024 | 80311 | 0.240 |
Why?
|
Contrast Media | 2 | 2016 | 5300 | 0.240 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 8 | 2021 | 11708 | 0.240 |
Why?
|
Image Enhancement | 1 | 2015 | 2877 | 0.240 |
Why?
|
Chromosomes, Human, Pair 22 | 1 | 2005 | 347 | 0.230 |
Why?
|
Magnetic Resonance Angiography | 3 | 2006 | 1429 | 0.230 |
Why?
|
Neurofibromin 2 | 1 | 2005 | 270 | 0.230 |
Why?
|
Temporal Muscle | 1 | 2023 | 36 | 0.230 |
Why?
|
Permeability | 2 | 2018 | 719 | 0.220 |
Why?
|
Antineoplastic Agents | 12 | 2021 | 13629 | 0.220 |
Why?
|
Growth Charts | 1 | 2023 | 60 | 0.220 |
Why?
|
Disease-Free Survival | 7 | 2017 | 6830 | 0.210 |
Why?
|
Diencephalon | 2 | 2005 | 54 | 0.210 |
Why?
|
Loss of Heterozygosity | 1 | 2005 | 659 | 0.210 |
Why?
|
Scoliosis | 4 | 2003 | 733 | 0.210 |
Why?
|
Diffusion | 2 | 2017 | 813 | 0.200 |
Why?
|
Heredodegenerative Disorders, Nervous System | 1 | 2002 | 16 | 0.200 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 3 | 2002 | 1067 | 0.200 |
Why?
|
Imaging, Three-Dimensional | 3 | 2013 | 4044 | 0.200 |
Why?
|
Developmental Disabilities | 2 | 2010 | 1504 | 0.200 |
Why?
|
Failure to Thrive | 2 | 2005 | 140 | 0.200 |
Why?
|
Brain Diseases, Metabolic | 1 | 2002 | 44 | 0.200 |
Why?
|
Optic Nerve Glioma | 1 | 2021 | 32 | 0.190 |
Why?
|
Guillain-Barre Syndrome | 1 | 2023 | 125 | 0.190 |
Why?
|
Nervous System Diseases | 2 | 2023 | 1647 | 0.190 |
Why?
|
Histones | 2 | 2023 | 2583 | 0.190 |
Why?
|
Meningioma | 2 | 2009 | 1220 | 0.180 |
Why?
|
Connective Tissue Diseases | 1 | 2023 | 286 | 0.180 |
Why?
|
Neoplasm Recurrence, Local | 9 | 2016 | 9274 | 0.170 |
Why?
|
Disease Progression | 8 | 2023 | 13503 | 0.170 |
Why?
|
Contractile Proteins | 1 | 2000 | 240 | 0.170 |
Why?
|
Prenatal Diagnosis | 4 | 2011 | 1267 | 0.170 |
Why?
|
Molecular Biology | 1 | 2023 | 581 | 0.170 |
Why?
|
Systemic Inflammatory Response Syndrome | 2 | 2023 | 621 | 0.170 |
Why?
|
Infant, Newborn | 18 | 2015 | 26169 | 0.170 |
Why?
|
Cranial Nerve Neoplasms | 2 | 1997 | 134 | 0.170 |
Why?
|
Combined Modality Therapy | 9 | 2021 | 8551 | 0.160 |
Why?
|
Choristoma | 1 | 2000 | 207 | 0.160 |
Why?
|
Ultrasonography, Prenatal | 6 | 2012 | 1748 | 0.160 |
Why?
|
Tectum Mesencephali | 1 | 1998 | 18 | 0.160 |
Why?
|
Photons | 2 | 2019 | 581 | 0.160 |
Why?
|
Guanine | 2 | 2011 | 278 | 0.160 |
Why?
|
Perfusion Imaging | 1 | 2020 | 196 | 0.160 |
Why?
|
Hydrocephalus | 4 | 2011 | 763 | 0.150 |
Why?
|
Prognosis | 10 | 2021 | 29640 | 0.150 |
Why?
|
Craniopharyngioma | 1 | 2020 | 277 | 0.150 |
Why?
|
Brain Diseases | 1 | 2007 | 1540 | 0.150 |
Why?
|
Neurosecretory Systems | 1 | 1999 | 221 | 0.150 |
Why?
|
Craniocerebral Trauma | 1 | 2002 | 491 | 0.150 |
Why?
|
Optic Chiasm | 1 | 1997 | 91 | 0.140 |
Why?
|
Endpoint Determination | 1 | 2020 | 597 | 0.140 |
Why?
|
Radiation Oncology | 1 | 2023 | 563 | 0.140 |
Why?
|
Dacarbazine | 2 | 2011 | 560 | 0.140 |
Why?
|
Polyethylene Glycols | 2 | 2020 | 1189 | 0.140 |
Why?
|
Endocrine System Diseases | 1 | 1999 | 251 | 0.140 |
Why?
|
Angiogenesis Inhibitors | 4 | 2013 | 2047 | 0.140 |
Why?
|
Interferon-alpha | 1 | 2020 | 919 | 0.130 |
Why?
|
Proto-Oncogene Proteins B-raf | 2 | 2024 | 2052 | 0.130 |
Why?
|
Microfilament Proteins | 1 | 2000 | 1134 | 0.120 |
Why?
|
Phenylketonurias | 1 | 1996 | 123 | 0.120 |
Why?
|
Pons | 2 | 2019 | 239 | 0.120 |
Why?
|
Pituitary Neoplasms | 3 | 2020 | 1313 | 0.120 |
Why?
|
Piperazines | 2 | 2021 | 2520 | 0.120 |
Why?
|
Indoles | 2 | 2016 | 1830 | 0.120 |
Why?
|
Radiography | 8 | 2023 | 6965 | 0.120 |
Why?
|
Anus, Imperforate | 1 | 1994 | 64 | 0.120 |
Why?
|
Niacinamide | 1 | 2016 | 414 | 0.120 |
Why?
|
Fetal Diseases | 2 | 2011 | 911 | 0.110 |
Why?
|
Ice | 1 | 2014 | 102 | 0.110 |
Why?
|
Orbital Diseases | 1 | 1996 | 178 | 0.110 |
Why?
|
Orbital Neoplasms | 1 | 1996 | 221 | 0.110 |
Why?
|
Radiotherapy Dosage | 4 | 2019 | 2897 | 0.110 |
Why?
|
Neoplasms, Nerve Tissue | 1 | 2013 | 21 | 0.110 |
Why?
|
Benchmarking | 1 | 2020 | 1040 | 0.110 |
Why?
|
Clinical Trials, Phase I as Topic | 3 | 2011 | 327 | 0.110 |
Why?
|
Hypoxia, Brain | 1 | 2014 | 138 | 0.110 |
Why?
|
Camptothecin | 2 | 2013 | 590 | 0.110 |
Why?
|
Protein Kinase Inhibitors | 3 | 2021 | 5640 | 0.100 |
Why?
|
Gene Deletion | 2 | 2006 | 2668 | 0.100 |
Why?
|
Neural Tube Defects | 1 | 1994 | 255 | 0.100 |
Why?
|
Cranial Irradiation | 1 | 1995 | 391 | 0.100 |
Why?
|
Maximum Tolerated Dose | 6 | 2011 | 877 | 0.100 |
Why?
|
Radionuclide Imaging | 3 | 2013 | 1975 | 0.100 |
Why?
|
Treatment Outcome | 17 | 2021 | 64968 | 0.100 |
Why?
|
Microcephaly | 1 | 1996 | 423 | 0.100 |
Why?
|
Survival Analysis | 4 | 2020 | 10185 | 0.100 |
Why?
|
Visual Pathways | 1 | 1996 | 534 | 0.100 |
Why?
|
Survival Rate | 6 | 2013 | 12806 | 0.100 |
Why?
|
Urogenital Abnormalities | 1 | 1994 | 256 | 0.100 |
Why?
|
ROC Curve | 3 | 2018 | 3570 | 0.100 |
Why?
|
DNA Mutational Analysis | 1 | 2020 | 4110 | 0.100 |
Why?
|
Telomerase | 1 | 2016 | 747 | 0.090 |
Why?
|
Septum Pellucidum | 1 | 2011 | 54 | 0.090 |
Why?
|
Neurofibromatoses | 2 | 2013 | 299 | 0.090 |
Why?
|
Young Adult | 14 | 2024 | 58673 | 0.090 |
Why?
|
Observer Variation | 7 | 2010 | 2596 | 0.090 |
Why?
|
Neurofibromatosis 2 | 1 | 2004 | 385 | 0.090 |
Why?
|
Adult | 33 | 2022 | 219843 | 0.090 |
Why?
|
Thallium Radioisotopes | 2 | 2002 | 138 | 0.090 |
Why?
|
Aspartic Acid | 2 | 2004 | 576 | 0.090 |
Why?
|
Reproducibility of Results | 5 | 2014 | 20045 | 0.090 |
Why?
|
Artificial Intelligence | 1 | 2024 | 2554 | 0.090 |
Why?
|
Neuroma, Acoustic | 1 | 2013 | 455 | 0.090 |
Why?
|
Antisickling Agents | 1 | 2010 | 72 | 0.090 |
Why?
|
Cerebral Arterial Diseases | 1 | 2010 | 82 | 0.080 |
Why?
|
Meningitis | 2 | 2006 | 218 | 0.080 |
Why?
|
National Cancer Institute (U.S.) | 2 | 2023 | 295 | 0.080 |
Why?
|
Radiology | 1 | 2023 | 2103 | 0.080 |
Why?
|
Kaplan-Meier Estimate | 3 | 2015 | 6546 | 0.080 |
Why?
|
Pregnancy Outcome | 4 | 2012 | 2906 | 0.080 |
Why?
|
Angiomatosis | 1 | 2009 | 46 | 0.080 |
Why?
|
Pyridines | 1 | 2021 | 2877 | 0.080 |
Why?
|
Neuroectodermal Tumors, Primitive | 2 | 2006 | 136 | 0.080 |
Why?
|
Hydroxyurea | 1 | 2010 | 283 | 0.080 |
Why?
|
Mutation | 3 | 2023 | 29951 | 0.080 |
Why?
|
Vision Disorders | 1 | 1996 | 1084 | 0.080 |
Why?
|
Follow-Up Studies | 12 | 2017 | 39256 | 0.080 |
Why?
|
Water | 1 | 2014 | 1402 | 0.080 |
Why?
|
Snake Venoms | 1 | 2008 | 40 | 0.080 |
Why?
|
Medulla Oblongata | 1 | 1999 | 248 | 0.080 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2010 | 629 | 0.080 |
Why?
|
Corpus Callosum | 2 | 2006 | 749 | 0.070 |
Why?
|
Head and Neck Neoplasms | 1 | 2002 | 2880 | 0.070 |
Why?
|
Monitoring, Intraoperative | 1 | 2014 | 941 | 0.070 |
Why?
|
Algorithms | 4 | 2020 | 13959 | 0.070 |
Why?
|
Prospective Studies | 10 | 2022 | 54265 | 0.070 |
Why?
|
Anisotropy | 1 | 2010 | 1278 | 0.070 |
Why?
|
Hemorrhage | 2 | 2013 | 3606 | 0.070 |
Why?
|
Minority Groups | 1 | 2014 | 1199 | 0.070 |
Why?
|
Palate, Soft | 1 | 2006 | 100 | 0.070 |
Why?
|
Radiotherapy | 2 | 2010 | 1505 | 0.070 |
Why?
|
Forecasting | 1 | 2015 | 2931 | 0.070 |
Why?
|
Hydrazines | 1 | 2008 | 224 | 0.070 |
Why?
|
Diagnosis, Differential | 3 | 2015 | 12968 | 0.070 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2002 | 4024 | 0.070 |
Why?
|
Perioperative Care | 1 | 2014 | 1032 | 0.070 |
Why?
|
Adenoma | 1 | 1996 | 2148 | 0.070 |
Why?
|
Emaciation | 1 | 2005 | 5 | 0.060 |
Why?
|
Mothers | 1 | 1996 | 2186 | 0.060 |
Why?
|
Brain Damage, Chronic | 2 | 1997 | 267 | 0.060 |
Why?
|
United States | 8 | 2023 | 72369 | 0.060 |
Why?
|
Supratentorial Neoplasms | 1 | 2006 | 159 | 0.060 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 1 | 2009 | 666 | 0.060 |
Why?
|
Central Nervous System | 2 | 2022 | 1334 | 0.060 |
Why?
|
Busulfan | 1 | 2006 | 258 | 0.060 |
Why?
|
Sensitivity and Specificity | 4 | 2016 | 14655 | 0.060 |
Why?
|
Tumor Burden | 2 | 2022 | 1898 | 0.060 |
Why?
|
Organoplatinum Compounds | 1 | 2006 | 410 | 0.060 |
Why?
|
Nerve Fibers, Myelinated | 1 | 2010 | 952 | 0.060 |
Why?
|
Rhabdoid Tumor | 1 | 2006 | 210 | 0.060 |
Why?
|
Collateral Circulation | 2 | 1997 | 292 | 0.060 |
Why?
|
Models, Theoretical | 1 | 2016 | 3561 | 0.060 |
Why?
|
Necrosis | 2 | 2019 | 1612 | 0.060 |
Why?
|
Predictive Value of Tests | 5 | 2020 | 15272 | 0.060 |
Why?
|
Craniofacial Abnormalities | 1 | 2006 | 315 | 0.060 |
Why?
|
Neoplasms | 2 | 2023 | 22066 | 0.060 |
Why?
|
Chromosomes, Human, X | 1 | 2006 | 320 | 0.060 |
Why?
|
Smith-Lemli-Opitz Syndrome | 1 | 2003 | 46 | 0.060 |
Why?
|
Metabolism, Inborn Errors | 1 | 2006 | 285 | 0.060 |
Why?
|
Brain Abscess | 2 | 1995 | 120 | 0.060 |
Why?
|
Prenatal Exposure Delayed Effects | 1 | 1996 | 2494 | 0.060 |
Why?
|
Teratoma | 1 | 2006 | 403 | 0.060 |
Why?
|
Cerebral Hemorrhage | 1 | 1995 | 2660 | 0.060 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2007 | 787 | 0.050 |
Why?
|
Utah | 1 | 2023 | 131 | 0.050 |
Why?
|
Endarterectomy | 1 | 1993 | 196 | 0.050 |
Why?
|
Analysis of Variance | 4 | 2011 | 6242 | 0.050 |
Why?
|
Cerebral Hemorrhage, Traumatic | 1 | 2002 | 20 | 0.050 |
Why?
|
Pyrroles | 1 | 2009 | 1137 | 0.050 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2006 | 619 | 0.050 |
Why?
|
Asphyxia Neonatorum | 1 | 2002 | 111 | 0.050 |
Why?
|
Quality of Life | 1 | 2023 | 13301 | 0.050 |
Why?
|
Proportional Hazards Models | 3 | 2011 | 12531 | 0.050 |
Why?
|
Leukodystrophy, Globoid Cell | 1 | 2001 | 38 | 0.050 |
Why?
|
Anemia, Sickle Cell | 1 | 2010 | 1056 | 0.050 |
Why?
|
Ultrasonography, Doppler, Duplex | 1 | 2002 | 200 | 0.050 |
Why?
|
Gestational Age | 4 | 2011 | 3564 | 0.050 |
Why?
|
Thalidomide | 1 | 2006 | 884 | 0.050 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2005 | 586 | 0.050 |
Why?
|
Alzheimer Disease | 1 | 2022 | 8551 | 0.050 |
Why?
|
Cerebral Cortex | 3 | 2007 | 5755 | 0.050 |
Why?
|
Skull Fractures | 1 | 2002 | 201 | 0.050 |
Why?
|
Osteoblastoma | 1 | 2000 | 24 | 0.050 |
Why?
|
Birth Injuries | 1 | 2002 | 150 | 0.050 |
Why?
|
Akinetic Mutism | 1 | 2000 | 11 | 0.040 |
Why?
|
Stroke | 1 | 2023 | 9946 | 0.040 |
Why?
|
Human Growth Hormone | 1 | 2005 | 638 | 0.040 |
Why?
|
Membrane Transport Proteins | 1 | 2006 | 1036 | 0.040 |
Why?
|
Neoplasm Staging | 2 | 2021 | 11141 | 0.040 |
Why?
|
Diffusion Tensor Imaging | 1 | 2010 | 2381 | 0.040 |
Why?
|
Pelvis | 1 | 2004 | 743 | 0.040 |
Why?
|
Tantalum | 1 | 1990 | 54 | 0.040 |
Why?
|
Spina Bifida Occulta | 1 | 1999 | 31 | 0.040 |
Why?
|
Pregnancy | 8 | 2012 | 29727 | 0.040 |
Why?
|
Hemostasis, Surgical | 1 | 1990 | 129 | 0.040 |
Why?
|
Postoperative Complications | 3 | 2014 | 15684 | 0.040 |
Why?
|
Fetus | 1 | 2006 | 1862 | 0.040 |
Why?
|
Scalp | 1 | 2002 | 389 | 0.040 |
Why?
|
Regression Analysis | 2 | 2007 | 6361 | 0.040 |
Why?
|
Carotid Arteries | 1 | 1993 | 951 | 0.040 |
Why?
|
Orthopedic Fixation Devices | 1 | 1998 | 76 | 0.040 |
Why?
|
Intestinal Pseudo-Obstruction | 1 | 1998 | 49 | 0.040 |
Why?
|
Pseudarthrosis | 1 | 1998 | 54 | 0.040 |
Why?
|
Recurrence | 2 | 2008 | 8487 | 0.040 |
Why?
|
Abdomen | 1 | 2004 | 1125 | 0.040 |
Why?
|
Administration, Oral | 2 | 2017 | 4045 | 0.040 |
Why?
|
Child Development | 1 | 2010 | 2280 | 0.040 |
Why?
|
Spine | 2 | 2022 | 1110 | 0.040 |
Why?
|
Quality Assurance, Health Care | 1 | 2008 | 2179 | 0.040 |
Why?
|
Sulfonamides | 1 | 2008 | 1973 | 0.040 |
Why?
|
Intelligence Tests | 1 | 1999 | 498 | 0.040 |
Why?
|
Pituitary Diseases | 1 | 1999 | 135 | 0.040 |
Why?
|
Cyclin-Dependent Kinase 6 | 1 | 2021 | 346 | 0.040 |
Why?
|
Hypothalamic Diseases | 1 | 1999 | 134 | 0.040 |
Why?
|
Neoplasm Seeding | 1 | 2018 | 85 | 0.040 |
Why?
|
Brain Edema | 1 | 2002 | 603 | 0.040 |
Why?
|
Skull | 1 | 2002 | 815 | 0.040 |
Why?
|
Purines | 1 | 2021 | 601 | 0.040 |
Why?
|
Lactic Acid | 1 | 2002 | 1132 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 4 | 2015 | 10828 | 0.040 |
Why?
|
Hedgehog Proteins | 1 | 2022 | 769 | 0.040 |
Why?
|
Tablets | 1 | 2017 | 149 | 0.040 |
Why?
|
Amyloid | 1 | 2022 | 843 | 0.040 |
Why?
|
Linear Energy Transfer | 1 | 2018 | 152 | 0.040 |
Why?
|
Radiotherapy, Adjuvant | 2 | 1999 | 1790 | 0.040 |
Why?
|
Aminopyridines | 1 | 2021 | 564 | 0.040 |
Why?
|
Texas | 1 | 2018 | 401 | 0.040 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2021 | 556 | 0.040 |
Why?
|
Spinal Cord | 2 | 2022 | 1817 | 0.040 |
Why?
|
Pia Mater | 1 | 1997 | 87 | 0.040 |
Why?
|
Cerebrospinal Fluid Shunts | 1 | 1998 | 195 | 0.030 |
Why?
|
Enzyme Inhibitors | 1 | 2007 | 3726 | 0.030 |
Why?
|
Statistics as Topic | 2 | 2015 | 2363 | 0.030 |
Why?
|
Florida | 1 | 2018 | 427 | 0.030 |
Why?
|
Tissue Distribution | 2 | 2011 | 2262 | 0.030 |
Why?
|
Relative Biological Effectiveness | 1 | 2018 | 312 | 0.030 |
Why?
|
Choline | 3 | 2004 | 513 | 0.030 |
Why?
|
Retreatment | 1 | 1998 | 600 | 0.030 |
Why?
|
Equipment Failure | 1 | 1998 | 577 | 0.030 |
Why?
|
Cerebral Angiography | 2 | 1997 | 1271 | 0.030 |
Why?
|
Syndrome | 2 | 2005 | 3278 | 0.030 |
Why?
|
World Health Organization | 1 | 2022 | 1319 | 0.030 |
Why?
|
Physicians | 1 | 2014 | 4590 | 0.030 |
Why?
|
Pituitary Gland | 1 | 1999 | 637 | 0.030 |
Why?
|
Statistics, Nonparametric | 2 | 2012 | 2852 | 0.030 |
Why?
|
Prolactinoma | 1 | 1996 | 113 | 0.030 |
Why?
|
Information Dissemination | 1 | 2024 | 1132 | 0.030 |
Why?
|
Blood Cell Count | 1 | 2016 | 398 | 0.030 |
Why?
|
Pneumothorax | 1 | 1998 | 377 | 0.030 |
Why?
|
Cancer Care Facilities | 1 | 2018 | 425 | 0.030 |
Why?
|
Likelihood Functions | 1 | 1998 | 988 | 0.030 |
Why?
|
Research Design | 1 | 2011 | 6181 | 0.030 |
Why?
|
Intestinal Obstruction | 1 | 1998 | 435 | 0.030 |
Why?
|
Mental Disorders | 1 | 1995 | 6797 | 0.030 |
Why?
|
Brain Chemistry | 3 | 2004 | 959 | 0.030 |
Why?
|
Hypothalamo-Hypophyseal System | 1 | 1999 | 698 | 0.030 |
Why?
|
Drug Monitoring | 1 | 2021 | 966 | 0.030 |
Why?
|
Cloaca | 1 | 1994 | 52 | 0.030 |
Why?
|
Phenylalanine | 1 | 1996 | 365 | 0.030 |
Why?
|
Biological Availability | 1 | 2015 | 395 | 0.030 |
Why?
|
Pyrimidines | 1 | 2007 | 3011 | 0.030 |
Why?
|
Empyema, Subdural | 1 | 1994 | 12 | 0.030 |
Why?
|
Hemolytic-Uremic Syndrome | 1 | 1995 | 106 | 0.030 |
Why?
|
Epilepsy, Temporal Lobe | 1 | 1998 | 387 | 0.030 |
Why?
|
Chemotherapy, Adjuvant | 2 | 1999 | 3531 | 0.030 |
Why?
|
Spinal Neoplasms | 1 | 2000 | 716 | 0.030 |
Why?
|
Moyamoya Disease | 1 | 1997 | 255 | 0.030 |
Why?
|
Cerebrovascular Circulation | 1 | 2004 | 2731 | 0.030 |
Why?
|
Alanine Transaminase | 1 | 2016 | 607 | 0.030 |
Why?
|
Meningoencephalitis | 1 | 1994 | 83 | 0.030 |
Why?
|
Carotid Artery Diseases | 1 | 1990 | 881 | 0.030 |
Why?
|
Feasibility Studies | 2 | 2019 | 5201 | 0.030 |
Why?
|
Child Abuse | 1 | 2002 | 1068 | 0.030 |
Why?
|
Age of Onset | 1 | 2020 | 3302 | 0.030 |
Why?
|
Dandy-Walker Syndrome | 1 | 1993 | 45 | 0.030 |
Why?
|
Oligonucleotides | 1 | 2016 | 588 | 0.030 |
Why?
|
Uncertainty | 1 | 2018 | 754 | 0.030 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 1999 | 2500 | 0.030 |
Why?
|
Drug Administration Schedule | 2 | 2013 | 4900 | 0.030 |
Why?
|
Pedigree | 1 | 2000 | 4577 | 0.030 |
Why?
|
Orbit | 1 | 1996 | 446 | 0.030 |
Why?
|
Medical Records | 1 | 1998 | 1407 | 0.030 |
Why?
|
Neuroglia | 1 | 1998 | 944 | 0.030 |
Why?
|
Arachnoid Cysts | 1 | 1993 | 61 | 0.030 |
Why?
|
Optic Nerve Diseases | 1 | 1996 | 342 | 0.030 |
Why?
|
Neurologic Examination | 1 | 1995 | 916 | 0.020 |
Why?
|
Radiotherapy, Intensity-Modulated | 1 | 2018 | 801 | 0.020 |
Why?
|
Time Factors | 3 | 2020 | 40141 | 0.020 |
Why?
|
Biomedical Research | 1 | 2007 | 3421 | 0.020 |
Why?
|
Glioblastoma | 1 | 2006 | 3482 | 0.020 |
Why?
|
Suppositories | 1 | 1980 | 16 | 0.020 |
Why?
|
Injections, Intravenous | 1 | 2013 | 1388 | 0.020 |
Why?
|
Medical Oncology | 1 | 2023 | 2321 | 0.020 |
Why?
|
Inpatients | 1 | 2023 | 2580 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2003 | 3697 | 0.020 |
Why?
|
Recombinant Proteins | 1 | 2020 | 6543 | 0.020 |
Why?
|
DNA Modification Methylases | 1 | 2011 | 208 | 0.020 |
Why?
|
Proteinuria | 1 | 2013 | 594 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 2013 | 1705 | 0.020 |
Why?
|
Consensus | 1 | 2020 | 3106 | 0.020 |
Why?
|
Bone Diseases | 1 | 2004 | 418 | 0.020 |
Why?
|
Encephalitis | 1 | 1994 | 436 | 0.020 |
Why?
|
Intracranial Aneurysm | 1 | 1990 | 1275 | 0.020 |
Why?
|
Disease Management | 1 | 2021 | 2508 | 0.020 |
Why?
|
Drug Therapy, Combination | 2 | 2011 | 6499 | 0.020 |
Why?
|
Brain Ischemia | 1 | 1993 | 3128 | 0.020 |
Why?
|
DNA Repair Enzymes | 1 | 2011 | 345 | 0.020 |
Why?
|
Ki-67 Antigen | 1 | 2011 | 631 | 0.020 |
Why?
|
Frontal Lobe | 1 | 1996 | 1422 | 0.020 |
Why?
|
Dilatation, Pathologic | 1 | 2010 | 527 | 0.020 |
Why?
|
Carcinogens | 1 | 1980 | 449 | 0.020 |
Why?
|
Lymphocytes | 1 | 2016 | 2612 | 0.020 |
Why?
|
Critical Care | 1 | 2021 | 2699 | 0.020 |
Why?
|
Patient Discharge | 1 | 2021 | 3476 | 0.020 |
Why?
|
Clostridium Infections | 1 | 1995 | 557 | 0.020 |
Why?
|
Age Factors | 2 | 2021 | 18416 | 0.020 |
Why?
|
Cerebral Arteries | 1 | 2010 | 493 | 0.020 |
Why?
|
Immunotherapy | 1 | 2023 | 4637 | 0.020 |
Why?
|
Cerebrovascular Disorders | 1 | 2004 | 1500 | 0.020 |
Why?
|
Pneumonia | 1 | 1998 | 2138 | 0.020 |
Why?
|
Aged | 6 | 2005 | 169002 | 0.020 |
Why?
|
Logistic Models | 3 | 2011 | 13315 | 0.020 |
Why?
|
Plasma Membrane Neurotransmitter Transport Proteins | 1 | 2006 | 22 | 0.020 |
Why?
|
Fatigue | 1 | 2013 | 1544 | 0.020 |
Why?
|
Constriction, Pathologic | 1 | 2010 | 1100 | 0.020 |
Why?
|
Choroid Plexus Neoplasms | 1 | 2006 | 38 | 0.020 |
Why?
|
Hallucinations | 1 | 2009 | 366 | 0.020 |
Why?
|
Blood Flow Velocity | 1 | 2010 | 1375 | 0.020 |
Why?
|
Cell Movement | 1 | 1998 | 5210 | 0.020 |
Why?
|
Prevalence | 2 | 2011 | 15684 | 0.020 |
Why?
|
Cerebellum | 1 | 1993 | 1495 | 0.020 |
Why?
|
Antibodies, Monoclonal | 1 | 2022 | 9196 | 0.020 |
Why?
|
Injections, Spinal | 1 | 2006 | 316 | 0.020 |
Why?
|
Massachusetts | 1 | 2018 | 8805 | 0.020 |
Why?
|
Hyperkinesis | 1 | 2005 | 89 | 0.020 |
Why?
|
Arthralgia | 1 | 2009 | 461 | 0.010 |
Why?
|
Nystagmus, Pathologic | 1 | 2005 | 105 | 0.010 |
Why?
|
Drug Interactions | 1 | 2009 | 1426 | 0.010 |
Why?
|
Cohort Studies | 2 | 2023 | 41316 | 0.010 |
Why?
|
Case-Control Studies | 3 | 1999 | 22040 | 0.010 |
Why?
|
Thioguanine | 1 | 2003 | 44 | 0.010 |
Why?
|
Procarbazine | 1 | 2003 | 172 | 0.010 |
Why?
|
Lomustine | 1 | 2003 | 60 | 0.010 |
Why?
|
Area Under Curve | 1 | 2008 | 1635 | 0.010 |
Why?
|
Hospitalization | 2 | 2021 | 10761 | 0.010 |
Why?
|
Neutrophils | 1 | 2016 | 3770 | 0.010 |
Why?
|
Hydrogen | 1 | 2003 | 171 | 0.010 |
Why?
|
Depressive Disorder | 1 | 1996 | 3728 | 0.010 |
Why?
|
Infusions, Intravenous | 1 | 2008 | 2235 | 0.010 |
Why?
|
Middle Aged | 8 | 2005 | 220179 | 0.010 |
Why?
|
Pandemics | 1 | 2023 | 8621 | 0.010 |
Why?
|
Intraoperative Period | 1 | 1993 | 516 | 0.010 |
Why?
|
Drug Evaluation | 1 | 2003 | 642 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2023 | 25927 | 0.010 |
Why?
|
Vomiting | 1 | 2005 | 649 | 0.010 |
Why?
|
Eye | 1 | 2006 | 710 | 0.010 |
Why?
|
Acoustic Impedance Tests | 1 | 1982 | 110 | 0.010 |
Why?
|
Protons | 1 | 2007 | 1113 | 0.010 |
Why?
|
Tumor Suppressor Proteins | 1 | 2011 | 2804 | 0.010 |
Why?
|
Benzamides | 1 | 2007 | 1370 | 0.010 |
Why?
|
Vincristine | 1 | 2003 | 1038 | 0.010 |
Why?
|
Photomicrography | 1 | 2000 | 71 | 0.010 |
Why?
|
Incidence | 1 | 2019 | 21379 | 0.010 |
Why?
|
Gamma Cameras | 1 | 2000 | 34 | 0.010 |
Why?
|
Tumor Microenvironment | 1 | 2013 | 3829 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2018 | 7469 | 0.010 |
Why?
|
Carboplatin | 1 | 2003 | 789 | 0.010 |
Why?
|
Stainless Steel | 1 | 1990 | 79 | 0.010 |
Why?
|
Treatment Failure | 1 | 2006 | 2646 | 0.010 |
Why?
|
Movement | 1 | 2006 | 1474 | 0.010 |
Why?
|
Hematologic Diseases | 1 | 2003 | 497 | 0.010 |
Why?
|
Twins, Monozygotic | 1 | 2001 | 469 | 0.010 |
Why?
|
Anticonvulsants | 1 | 2009 | 1881 | 0.010 |
Why?
|
Syringomyelia | 1 | 1999 | 67 | 0.010 |
Why?
|
Boston | 1 | 2011 | 9283 | 0.010 |
Why?
|
Bone Diseases, Developmental | 1 | 1999 | 131 | 0.010 |
Why?
|
Diagnostic Errors | 1 | 2005 | 1266 | 0.010 |
Why?
|
Lumbosacral Region | 1 | 1999 | 291 | 0.010 |
Why?
|
Mice, Nude | 1 | 2004 | 3605 | 0.010 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2005 | 1920 | 0.010 |
Why?
|
Nerve Compression Syndromes | 1 | 1999 | 160 | 0.010 |
Why?
|
Hydrocortisone | 1 | 2005 | 1798 | 0.010 |
Why?
|
Celiac Disease | 1 | 2005 | 822 | 0.010 |
Why?
|
Spinal Dysraphism | 1 | 1999 | 174 | 0.010 |
Why?
|
Magnetics | 1 | 1990 | 600 | 0.010 |
Why?
|
Spinal Cord Compression | 1 | 1999 | 235 | 0.010 |
Why?
|
Intraoperative Care | 1 | 2000 | 768 | 0.010 |
Why?
|
Ultrasonography | 1 | 2010 | 5960 | 0.010 |
Why?
|
Kidney Transplantation | 1 | 1981 | 4215 | 0.010 |
Why?
|
Electroencephalography | 2 | 1998 | 6184 | 0.010 |
Why?
|
Aged, 80 and over | 2 | 1995 | 58953 | 0.010 |
Why?
|
Evaluation Studies as Topic | 1 | 1997 | 1628 | 0.010 |
Why?
|
Phosphorylation | 1 | 2006 | 8314 | 0.010 |
Why?
|
Cholesterol | 1 | 2003 | 2925 | 0.010 |
Why?
|
Oxygen | 1 | 2006 | 4190 | 0.010 |
Why?
|
Models, Structural | 1 | 1993 | 341 | 0.010 |
Why?
|
Gadolinium | 1 | 1998 | 958 | 0.010 |
Why?
|
Metronidazole | 1 | 1995 | 231 | 0.010 |
Why?
|
AIDS Dementia Complex | 1 | 1994 | 153 | 0.010 |
Why?
|
Genotype | 1 | 2008 | 12959 | 0.010 |
Why?
|
Hypertension | 1 | 2013 | 8595 | 0.010 |
Why?
|
Cisterna Magna | 1 | 1993 | 39 | 0.010 |
Why?
|
Liver | 1 | 2009 | 7510 | 0.010 |
Why?
|
Nerve Tissue Proteins | 1 | 2006 | 4409 | 0.010 |
Why?
|
Melanoma | 1 | 1981 | 5694 | 0.010 |
Why?
|
Postoperative Period | 1 | 1997 | 1821 | 0.010 |
Why?
|
Penicillins | 1 | 1995 | 403 | 0.010 |
Why?
|
Skin Neoplasms | 1 | 1981 | 5797 | 0.010 |
Why?
|
Life Expectancy | 1 | 1998 | 1249 | 0.010 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 1994 | 661 | 0.010 |
Why?
|
Risk Assessment | 1 | 2011 | 24086 | 0.010 |
Why?
|
Nevus, Pigmented | 1 | 1981 | 221 | 0.010 |
Why?
|
Models, Biological | 1 | 2005 | 9468 | 0.000 |
Why?
|
Phenotype | 1 | 2006 | 16543 | 0.000 |
Why?
|
Congenital Abnormalities | 1 | 1993 | 704 | 0.000 |
Why?
|
Psychiatric Status Rating Scales | 1 | 1996 | 6017 | 0.000 |
Why?
|
Severity of Illness Index | 1 | 2003 | 15828 | 0.000 |
Why?
|
Immunity, Cellular | 1 | 1981 | 1558 | 0.000 |
Why?
|
Disease Models, Animal | 1 | 2004 | 18135 | 0.000 |
Why?
|
Risk Factors | 1 | 2011 | 74278 | 0.000 |
Why?
|
Double-Blind Method | 1 | 1998 | 12412 | 0.000 |
Why?
|
Compliance | 1 | 1982 | 100 | 0.000 |
Why?
|
Air Pressure | 1 | 1982 | 74 | 0.000 |
Why?
|
Neoplasm Metastasis | 1 | 1981 | 4891 | 0.000 |
Why?
|
Ear Diseases | 1 | 1982 | 177 | 0.000 |
Why?
|
Otitis Media | 1 | 1982 | 285 | 0.000 |
Why?
|
Mice | 1 | 2004 | 81212 | 0.000 |
Why?
|
Animals | 2 | 2004 | 167935 | 0.000 |
Why?
|
Rats | 1 | 1980 | 23697 | 0.000 |
Why?
|